Current knowledge about HPV infection

1. C53 – Hrdlo děložní – cervicis uteri, ženy, srovnání incidence v ČR s ostatními zeměmi Evropy, přepočet na 100 000 osob. 2015, Ústav zdravotnických informací a statistiky ČR, URL: http://www.svod.cz/graph/?sessid=hs4f0rfuklirjvnu08j46rqtv5&typ=zahranici_2008&diag=C53&incmor=inc&pohl=z&kraj=w&vek_od=0&vek_do=18&zobrazeni=table&incidence=1&mortalita=1&vypocet=c&obdobi_od=1977&obdobi_do=2013&stadium=&t=&n=&m=&pt=&pn=&pm=&t=&n=&zije=&umrti=&lecba=&ref=.

2. C53 – ZN hrdla děložního – cervicis uteri, ženy, časový vývoj, počet případů na 100 000 osob. 2015, Ústav zdravotnických informací a statistiky ČR, URL: http://www.svod.cz/graph/?sessid=hs4f0rfuklirjvnu08j46rqtv5&typ=incmor&diag=C53&pohl=z&kraj=&vek_od=1&vek_do=18&zobrazeni=table&incidence=1&mortalita=1&mi=0&vypocet=c&obdobi_od=1977&obdobi_do=2013&stadium=&t=&n=&m=&pt=&pn=&pm=&t=&n=&zije=&umrti=&lecba=.

3. Ault, KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol, 2006, Suppl., p. 40470.

4. Bartsch, D., Boye, B., Baust, C., et al. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J, 1992, 11, 6, p. 2283–2291.

5. Braun, L., Durst, M., Mikumo, R., Gruppuso, P. Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor beta 1. Cancer Res, 1990, 50, 22, p. 7324–7332.

6. Burk, RD., Ho, GY., Beardsley, L., et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis, 1996, 174, 4, p. 679–689.

7. Casalegno, JS., Le Bail Carval, K., Eibach, D., et al. High risk HPV contamination of endocavity vaginal ultrasound probes: an underestimated route of nosocomial infection? PLoS One, 2012, 7, 10, p. e48137.

8. Cibula, D., Petružela, L., a kolektiv. Onkogynekologie. 1. ed. Praha: Grada Publishing, 2009, s. 311–339.

9. Clifford, GM., Smith, JS., Plummer, M., et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 2003, 88, 1, p. 63–73.

10. Cuzick, J., Clavel, C., Petry, KU., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 2006, 119, 5, p. 1095–1101.

11. de Sanjose, S., Alemany, L., Ordi, J., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer, 2013, 49, 16, p. 3450–3461.

12. de Villiers, EM., Fauquet, C., Broker, TR., et al. Classification of papillomaviruses. Virology, 2004, 324, 1, p. 17–27.

13. De Vuyst, H., Clifford, GM., Nascimento, MC., et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer, 2009, 124, 7, p. 1626–1636.

14. Dillner, J., Rebolj, M., Birembaut, P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ, 2008, 337, p. a1754.

15. Dunne, EF., Unger, ER., Sternberg, M., et al. Prevalence of HPV infection among females in the United States. JAMA, 2007, 297, 8, p. 813–819.

16. Figueroa, JP., Ward, E., Luthi, TE., et al. Prevalence of human papillomavirus among STD clinic attenders in Jamaica: association of younger age and increased sexual activity. Sex Transm Dis, 1995, 22, 2, p. 114–118.

17. Gall, SA. Female genital warts: global trends and treatments. Infect Dis Obstet Gynecol, 2001, 9, 3, p. 149–154.

18. Ho, GY., Bierman, R., Beardsley, L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 1998, 338, 7, p. 423–428.

19. Hoyer, H., Scheungraber, C., Kuehne-Heid, R., et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer, 2005, 116, 1, p. 136–143.

20. Huh, WK., Ault, KA., Chelmow, D., et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol, 2015, 136, 2, p. 178–182.

21. Chen, TM., Pecoraro, D., Defendi, V. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. Cancer Res, 1993, 53, 5, p. 1167–1171.

22. Chen, Z., Kamath, P., Zhang, S., et al. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther, 1995, 2, 4, p. 263–271.

23. Chow, LT., Broker, TR., Steinberg, BM. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS, 2010, 118, 6–7, p. 422–449.

24. Jastreboff, AM., Cymet, T. Role of the human papilloma virus in the development of cervical intraepithelial neoplasia and malignancy. Postgrad Med J, 2002, 78, 918, p. 225–228.

25. Jayasinghe, Y., Garland, SM. Genital warts in children: what do they mean? Arch Dis Child, 2006, 91, 8, p. 696–700.

26. Joseph, DA., Miller, JW., Wu, X., et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer, 2008, 113, 10, Suppl., p. 2892–2900.

27. Juckett, G., Hartman-Adams, H. Human papillomavirus: clinical manifestations and prevention. Am Fam Physician, 2010, 82, 10, p. 1209–1213.

28. Khan, MA., Tolleson, WH., Gangemi, JD., Pirisi, L. Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons. J Virol, 1993, 67, 6, p. 3396–3403.

29. Khan, MJ., Castle, PE., Lorincz, AT., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst, 2005, 97, 14, p. 1072–1079.

30. Kondo, K., Uenoyama, A., Kitagawa, R., et al. Genotype distribution of human papillomaviruses in Japanese women with abnormal cervical cytology. Open Virol J, 2012, 6, p. 277–283.

31. Laco, J. Lidské papilomaviry a jejich úloha v etiopatogenezi dlaždicobuněčného karcinomu dutiny ústní a orofaryngu. 1. ed. Praha: Galén, 2012.

32. Li, N., Franceschi, S., Howell-Jones, R., et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer, 2011, 128, 4, p. 927–935.

33. Maglennon, GA., McIntosh, P., Doorbar, J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology, 2011, 414, 2, p. 153–163.

34. Monk, BJ., Burger, RA., Lin, F., et al. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol, 1995, 85, 5 Pt 1, p. 709–715.

35. Moscicki, AB. Conservative management of adolescents with abnormal cytology and histology. J Natl Compr Canc Netw, 2008, 6, 1, p. 101–106.

36. Motoyama, S., Ladines-Llave, CA., Luis Villanueva, S., Maruo, T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci, 2004, 50, 1–2, p. 9–19.

37. Myers, ER., McCrory, DC., Nanda, K., et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol, 2000, 151, 12, p. 1158–1171.

38. NIH. Cervical Cancer Screening Programs in 19 ICSN Countries, 2012: Organization, Policies, and Program Reach. In.: National Institutes of Health, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, 2012.

39. Oliveira, A., Verdasca, N., Pista, A. Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia. J Med Virol, 2013, 85, 7, p. 1235–1241.

40. Parkin, DM., Bray, F. Chapter 2: The burden of HPV-related cancers. Vaccine, 2006, 24, Suppl. 3, p. S3/11–25.

41. Paulo, M., Borges, AB., Duarte, G., et al. The environmental cofactors in carcinogenesis in high risk HPV/HIV-positive women. Braz J Infect Dis, 2007, 11, 2, p. 189–195.

42. Peltecu, G., Bari, M., Lancu, G., Popa, F. Human papilloma virus and cervical preinvasive disease. J Med Life, 2009, 2, 4, p. 373–377.

43. Pham, TH., Nguyen, TH., Herrero, R., et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer, 2003, 104, 2, p. 213–220.

44. Ronco, G., Dillner, J., Elfstrom, KM., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, 2014, 383, 9916, p. 524–532.

45. Roztočil, A. Moderní gynekologie. 1. ed.: Praha, Grada Publishing, 2011, s. 330–343.

46. Sarid, R., Gao, SJ. Viruses and human cancer: from detection to causality. Cancer Lett, 2011, 305, 2, p. 218–227.

47. Sherman, ME., Lorincz, AT., Scott, DR., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst, 2003, 95, 1, p. 46–52.

48. Schiffman, M., Wentzensen, N., Wacholder, S., et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst, 2011, 103, 5, p. 368–383.

49. Smith, JS., Lindsay, L., Hoots, B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer, 2007, 121, 3, p. 621–632.

50. Soto, U., Das, BC., Lengert, M., et al. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene, 1999, 18, 21, p. 3187–3198.

51. Storey, A., Thomas, M., Kalita, A., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 1998, 393, 6682, p. 229–234.

52. Strander, B., Andersson-Ellstrom, A., Milsom, I., Sparen, P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ, 2007, 335, 7629, p. 1077.

53. Syrjanen, K., Syrjanen, S. Epidemiology of human papilloma virus infections and genital neoplasia. Scand J Infect Dis Suppl, 1990, 69, p. 7–17.

54. Tchernev, G. Sexually transmitted papillomavirus infections: epidemiology pathogenesis, clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options. An Bras Dermatol, 2009, 84, 4, p. 377–389.

55. Tjalma, WA., Fiander, A., Reich, O., et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer, 2013, 132, 4, p. 854–867.

56. Turyna, R., Sláma, J. Kolposkopie děložního hrdla. 1. ed. Galén, 2010.

57. Vaccarella, S., Soderlund-Strand, A., Franceschi, S., et al. Patterns of human papillomavirus types in multiple infections: an analysis in women and men of the high throughput human papillomavirus monitoring study. PLoS One, 2013, 8, 8, p. e71617.

58. van de Nieuwenhof, HP., van Kempen, LC., de Hullu, JA., et al. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol Biomarkers Prev, 2009, 18, 7, p. 2061–2067.

59. Vernon, SD., Hart, CE., Reeves, WC., Icenogle, JC. The HIV-1tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res, 1993, 27, 2, p. 133–145.

60. Vink, MA., Bogaards, AJ., Meijer, CJ., Berkhof, J. Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended? Int J Cancer, 2015, 137, 2, p. 420–427.

61. Walboomers, JM., Jacobs, MV., Manos, MM., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189, 1, p. 12–19.

62. Winer, RL., Lee, SK., Hughes, JP., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol, 2003, 157, 3, p. 218–226.

63. Woodworth, CD., Notario, V., DiPaolo, JA. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV--immortalized human genital epithelial cells. J Virol, 1990, 64, 10, p. 4767–4775.

64. Yang, HJ. Aberrant DNA methylation in cervical carcinogenesis. Chin J Cancer, 2013, 32, 1, p. 42–48.

65. Yim, EK., Park, JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat, 2005, 37, 6, p. 319–324.

66. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2002, 2, 5, p. 342–350.